Previous work from our laboratory has shown that MEK inhibitor (MEKi) treatment increases PD-L1 and MHC-I expression in two breast cancer lines, and that MEKi/PD-L1 combination treatment inhibits tumor growth compared to either single agent treatment in mice[7]. This evidence concerns the gene MAP2K7 and breast cancer.